Search results
Showing 196 to 210 of 1334 results for long term conditions
Evidence-based recommendations on exagamglogene autotemcel (Casgevy) for transfusion-dependent beta-thalassaemia in people 12 years and over.
Evidence-based recommendations on ribociclib (Kisqali) with an aromatase inhibitor for the adjuvant treatment of hormone receptor-positive, HER2-negative, early breast cancer at high risk of recurrence in adults.
Show all sections
Evidence-based recommendations on talquetamab (Talvey) for treating relapsed and refractory multiple myeloma after 3 or more treatments in adults.
Tenofovir disoproxil for the treatment of chronic hepatitis B (TA173)
Evidence-based recommendations on tenofovir disoproxil for treating chronic hepatitis B.
Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma (TA677)
Evidence-based recommendations on brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma in adults who have previously had a Bruton’s tyrosine kinase (BTK) inhibitor.
Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (NG128)
This guideline covers interventions in the acute stage of a stroke or transient ischaemic attack (TIA). It offers the best clinical advice on the diagnosis and acute management of stroke and TIA in the 48 hours after onset of symptoms.
This quality standard covers admissions into, and discharge from, inpatient hospital settings for adults (aged 18 years and over) with social care needs. It describes high-quality care in priority areas for improvement.
View quality statements for QS136Show all sections
Sections for QS136
- Quality statements
- Quality statement 1: Information sharing on admission
- Quality statement 2: Comprehensive geriatric assessment
- Quality statement 3: Coordinated discharge
- Quality statement 4: Discharge plans
- Quality statement 5: Involving carers in discharge planning
- Update information
- About this quality standard
Burosumab for treating X-linked hypophosphataemia in children and young people (HST8)
Evidence-based recommendations on burosumab (Crysvita) for X-linked hypophosphataemia in children and young people.
People's experience using adult social care services (QS182)
This quality standard covers the experience of adults using social care services. It applies to all settings where people use social care services, including people's own homes, residential care and community settings. Its aim is to help people understand what care they can expect and to improve their experience by supporting them to make decisions about their care. It describes high-quality care in priority areas for improvement.
View quality statements for QS182Show all sections
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
Evidence-based recommendations on avalglucosidase alfa (Nexviadyme) for Pompe disease.
Evidence-based recommendations on pembrolizumab (Keytruda) plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancer in adults.
Chronic obstructive pulmonary disease in over 16s: diagnosis and management (NG115)
This guideline covers diagnosing and managing chronic obstructive pulmonary disease or COPD (which includes emphysema and chronic bronchitis) in people aged 16 and older. It aims to help people with COPD to receive a diagnosis earlier so that they can benefit from treatments to reduce symptoms, improve quality of life and keep them healthy for longer.
Vamorolone for treating Duchenne muscular dystrophy in people 4 years and over (TA1031)
Evidence-based recommendations on vamorolone (Agamree) for treating Duchenne muscular dystrophy in people 4 years and over.
Show all sections
Spesolimab for treating generalised pustular psoriasis flares (TA1070)
Evidence-based recommendations on spesolimab (Spevigo) for treating generalised pustular psoriasis flares in adults.